Aqua Bounty Technologies, Inc. FDA approves AquAdvantage Salmon (3318G)
20 November 2015 - 1:46AM
UK Regulatory
TIDMABTX
RNS Number : 3318G
Aqua Bounty Technologies, Inc.
19 November 2015
19 November 2015
AQUABOUNTY TECHNOLOGIES, INC.
("AquaBounty" or the "Company")
FDA Approves AquAdvantage(R) Salmon
AquaBounty Technologies, Inc. (AIM: ABTU; OTC: AQBT), a
biotechnology company focused on enhancing productivity in
aquaculture, and a majority-owned subsidiary of Intrexon
Corporation (NYSE: XON), announces today that the U.S. Food and
Drug Administration (FDA) has approved the Company's New Animal
Drug Application for the production, sale, and consumption of its
AquAdvantage(R) Salmon, an Atlantic salmon that has been
genetically enhanced to reach market size in less time than
conventional farmed Atlantic salmon.
Ronald L. Stotish, Ph.D., Chief Executive Officer of AquaBounty,
commented, "AquAdvantage Salmon is a game-changer that brings
healthy and nutritious food to consumers in an environmentally
responsible manner without damaging the ocean and other marine
habitats. Using land-based aquaculture systems, this rich source of
protein and other nutrients can be farmed close to major consumer
markets in a more sustainable manner."
The U.S. currently imports over 90% of all the seafood, and more
specifically over 95% of the Atlantic salmon, it consumes.
AquAdvantage Salmon will offer the opportunity for an economically
viable domestic aquaculture industry while providing consumers a
fresh and delicious product.
Through greater efficiency and localized production,
AquaBounty's AquAdvantage Salmon increases productivity while
reducing costs and the environmental impacts associated with
current salmon farming operations. Land-based aquaculture systems
can provide a continuous supply of fresh, safe, traceable, and
sustainable AquAdvantage Salmon to communities across the U.S. and
do it with a reduced carbon footprint. Importantly, it offers an
alternative approach to fish farming that does not exploit the
oceans.
Jack A. Bobo, Senior Vice President and Chief Communications
Officer at Intrexon, stated, "The U.S. Dietary Guidelines Advisory
Committee encourages Americans to eat a wide variety of
seafood-including wild caught and farmed-as part of a healthy diet
rich in healthy fatty acids. However, this must occur in an
environmentally friendly and sustainable manner. FDA's approval of
the AquAdvantage Salmon is an important step in this
direction."
For further information, please contact:
AquaBounty Technologies +1 978 648 6048
David Frank, Chief Financial Officer
Stifel Nicolaus Europe Limited +44 (0)20 7710 7600
Stewart Wallace
Luther Pendragon +44 (0)20 7618 9100
Harry Chathli, Claire Norbury
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPKCDQQBDDPDD
(END) Dow Jones Newswires
November 19, 2015 09:46 ET (14:46 GMT)
Aqua Bounty (LSE:ABTX)
Historical Stock Chart
From Apr 2024 to May 2024
Aqua Bounty (LSE:ABTX)
Historical Stock Chart
From May 2023 to May 2024